Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.620
+0.050 (3.18%)
Oct 28, 2026, 4:00 PM EDT - Market closed
Inhibikase Therapeutics Market Cap
Inhibikase Therapeutics has a market cap or net worth of $294.96 million as of October 28, 2026. It is the 18,159th most valuable company in the world and the 3,218th biggest in the United States. Its market cap has increased by 110.01% in one year.
Market Cap
294.96M
Enterprise Value
135.94M
1-Year Change
110.01%
Global Rank
Country Rank
#3,218 United States
Category
ChartMarket Cap Chart
Since the IPO on December 23, 2020, Inhibikase Therapeutics's market cap has increased from $100.46M to $294.96M, an increase of 193.62%. That is a compound annual growth rate of 20.22%.
| Date | Market Cap | % Change |
|---|---|---|
| Oct 28, 2026 | 294.96M | 5.19% |
| Dec 31, 2025 | 280.40M | -3.25% |
| Dec 31, 2024 | 289.83M | 3,596.14% |
| Dec 29, 2023 | 7.84M | -37.83% |
| Dec 30, 2022 | 12.61M | -65.89% |
| Dec 31, 2021 | 36.98M | -46.68% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 23, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| vTv Therapeutics | 319.57M |
| Benitec Biopharma | 306.97M |
| Opus Genetics | 306.16M |
| Eikon Therapeutics | 300.07M |
| SAB Biotherapeutics | 291.16M |
| Fulcrum Therapeutics | 286.11M |
| Rocket Pharmaceuticals | 283.22M |
| Vicore Pharma Holding AB | 281.14M |